Cardiff Oncology, Inc.
CRDF
$2.41
-$0.03-1.23%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -17.89% | -3.61% | 40.16% | 49.78% | 61.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -17.89% | -3.61% | 40.16% | 49.78% | 61.41% |
| Cost of Revenue | 24.40% | 23.60% | 12.16% | 10.68% | 12.75% |
| Gross Profit | -25.27% | -24.14% | -11.74% | -10.10% | -12.06% |
| SG&A Expenses | 12.16% | 2.11% | -4.30% | -8.96% | -11.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.16% | 17.34% | 7.48% | 4.83% | 5.20% |
| Operating Income | -21.74% | -17.63% | -7.13% | -4.36% | -4.65% |
| Income Before Tax | -24.87% | -21.44% | -9.63% | -5.34% | -3.07% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.87% | -21.44% | -9.63% | -5.34% | -3.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.87% | -21.44% | -9.63% | -5.34% | -3.07% |
| EBIT | -21.74% | -17.63% | -7.13% | -4.36% | -4.65% |
| EBITDA | -22.02% | -17.82% | -7.18% | -4.33% | -4.55% |
| EPS Basic | 3.48% | -3.84% | -3.20% | -3.82% | -2.20% |
| Normalized Basic EPS | 3.45% | -3.86% | -3.19% | -3.80% | -2.18% |
| EPS Diluted | 3.48% | -3.84% | -3.20% | -3.82% | -2.20% |
| Normalized Diluted EPS | 3.45% | -3.86% | -3.19% | -3.80% | -2.18% |
| Average Basic Shares Outstanding | 30.90% | 18.87% | 6.65% | 1.39% | 0.93% |
| Average Diluted Shares Outstanding | 30.90% | 18.87% | 6.65% | 1.39% | 0.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |